News

This new late-breaking data presented at ACR 2023 was the first clinical evidence indicating efficacy of afimetoran for those with CLE.

New data presented at ACR 2023 highlighted the differences in rates of flares and Boolean 2.0 remission rates compared to patients with rheumatoid arthritis who continued TNFi.

In this research presented at ACR 2023, a connection between antiphospholipid antibodies and a greater potential risk of cardiovascular disease was identified.

This data represented the first-ever research presented at ACR on both fractures and calcium pyrophosphate deposition disease.

This segment of Dr. Fakih’s interview featured a discussion on the implications of his team’s findings presented at ACR 2023.

This research into improving quality measures for lupus patients was presented at ACR 2023 and funded by the CDC.

This research into obinutuzumab may provide some hope for those facing the most common cause of kidney damage among patients with lupus.

This data presented at ACR 2023 may provide relief to pregnant mothers as many stop taking them out of fear of harm to the fetus.

This new program was designed to be a scalable model for the formulation of similar initiatives in communities known to have limited access to specialized care for rheumatic conditions.

This new research presented at ACR Convergence 2023 led to several notable findings for patients with rheumatoid arthritis.

At the 7-month mark, multivariate analysis revealed patients with psoriasis aged ≥65 years reported a significantly better response to tildrakizumab.

Syndesmophyte development was 4 times more probable when patients had a clinical or radiographic description of axial involvement combined with elevated C-reactive protein.

Despite the lack of association with all-cause mortality, this research emphasizes the value of focusing on patients’ psychological well-being due to increased suicide risk among fibromyalgia patients.

Richard Johnson, MD, discusses the results of a study from ASN Kidney Week 2023 detailing the effects of urate-lowering therapy on blood pressure among patients with gout.

An analysis of data from 26 patients with repeat kidney biopsies in the AURORA program suggests voclosporin (Lupkynis) reduces proteinuria without causing harm in lupus nephritis patients.

Results of a recent study indicated rheumatology ultrasound clinics may play an increasingly central and dynamic role in rheumatology practices.

An analysis of the MIRROR trial from ASN Kidney Week 2023 details the effects of urate-lowering therapy on blood pressure among patients with uncontrolled gout receiving pegloticase plus methotrexate in the phase 4 trial.

Rosalind Ramsey-Goldman, MD, discusses her study, “The impact of US abortion policy on rheumatology clinical practice: a cross-sectional survey of rheumatologists.”

A retrospective analysis of data from the US National Inpatient Sample revealed the prevalence of fibromyalgia and chronic fatigue syndrome was significantly increased in patients with IBS compared to those without IBS.

The FDA has expanded the approval of abatacept (Orencia) for the treatment of active psoriatic arthritis in patients aged 2 years and older.

The introduction of an ICD-10 code specific to IgG4-Related Disease offers a promising opportunity to revolutionize patient care, enable more accurate diagnoses, and improve outcomes.

Results from a large observational retrospective cohort of ≥500 patients with PsA show relatively low drug persistence of apremilast, an oral PDE4 inhibitor.

24-week results from the UPREAL show higher efficacy of upadacitinib among males with PsA, bio-naïve patients, and those with elevated baseline C-reactive protein.

Many studies support the finding that biologic therapy reduces the presence of psoriatic arthritis—or the risk of developing arthritis in psoriatic patients—but other research suggest the opposite.

Esme Fuller-Thomson, PhD, MSW, discusses findings from her recent study about psychiatric disorders and mental health in patients with arthritis.

A cross-sectional study of survey data shows more than 50% of psoriasis and over 60% of psoriatic arthritis patients have depressive symptoms, with results drawing a link between functional impairment and the likelihood of depressive symptoms.

While Black people are consistently underrepresented, White people are consistently overrepresented in inflammatory arthritis trials for rheumatoid arthritis, psoriatic arthritis, spondyloarthritis, and juvenile idiopathic arthritis.

Results from Mendelian randomization analyses revealed PsO and PsA did not increase the risk of basal cell carcinoma, cutaneous squamous cell carcinoma, or cutaneous melanoma.

Sex, age at disease onset, and psoriatic arthritis were associated with the greatest impact on major life-changing decisions in patients with psoriasis.

The real-world evidence study examined patients with PsA taking secukinumab and ixekizumab, highlighting 80% treatment persistence after 1 year.